Jazz Pharmaceuticals PLC logo

Jazz Pharmaceuticals PLC

JAZZ
Healthcare|Biotechnology|Ireland
$243.79
-3.09 (-1.25%)
DCF (FCF)
$213.42
Earnings Power
$74.91

Upcoming Data Readouts (34)

Jul 2026
Est. completion
P1Extensive Stage Lung Small Cell Carcinoma
Palliative Radiotherapy With Lurbinectedin in Patients With Extensive Stage Small Cell Lung Cancer
NCT05244239n=22
Jul 2026
Est. completion
P3Gastric Neoplasms
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
NCT05152147n=920
Sep 2026
Est. completion
P2Glioblastoma
ARISTOCRAT: Blinded Trial of Temozolomide +/- Cannabinoids
NCT05629702n=120
Dec 2026
Est. completion
P1P2Acute Myeloid Leukemia (AML) in Remission
Phase IB/II of CPX-351 for Relapse Prevention in AML
NCT04990102n=24
Dec 2026
Est. completion
P1Ovarian Cancer
Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer
NCT05636111n=34
Dec 2026
Est. completion
P1Relapsed Pediatric AML
Vyxeos® With Clofarabine for Pediatric AML
NCT07156435n=25
Dec 2026
Est. completion
P2Breast Cancer
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
NCT06695845n=200
Feb 2027
Est. completion
P2Autism Spectrum Disorder
Cannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (ASD)
NCT03202303n=100
Feb 2027
Est. completion
Lennox Gastaut Syndrome
Epidyolex® in Lennox Gastaut, Dravet Syndrome and Tuberous Sclerosis Complex: an Observational Study in ITALY
NCT05485831n=111
Feb 2027
Est. completion
P1Acute Myeloid Leukemia With FLT3/ITD Mutation
Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML
NCT05024552n=22
Apr 2027
Est. completion
P1Acute Myeloid Leukemia
CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML
NCT05558124n=18
May 2027
Est. completion
P1Diffuse Midline Glioma (DMG)
ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
NCT04732065n=208
Jun 2027
Est. completion
P3Acute Myeloid Leukemia
Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics
NCT03897127n=882
Jul 2027
Est. completion
P1P2Ewing Sarcoma
Lurbinectedin in FET-Fused Tumors
NCT05918640n=63
Aug 2027
Est. completion
P4Lennox Gastaut Syndrome
Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution
NCT05044819n=154
Nov 2027
Est. completion
P1Focal Seizures
A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures
NCT07233239n=100
Nov 2027
Est. completion
P1Advanced Solid Tumor
JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors
NCT06108050n=177
Dec 2027
Est. completion
P2Diffuse Intrinsic Pontine Glioma
Combination Therapy for the Treatment of Diffuse Midline Gliomas
NCT05009992n=360
Jan 2028
Est. completion
P2HER2-positive Breast Cancer
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
NCT07102381n=125
Jan 2028
Est. completion
P1P2Refractory Ewing Sarcoma
Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma
NCT05734066n=60

Awaiting Results (10)

Trials past primary completion date but still active — data readout may be imminent.

Jul 2026
P1P2
Lurbinectedin + Doxorubicin In Leiomyosarcoma
NCT05099666
Jul 2026
Long-Term Follow-Up of a Cohort of Participants Prescribed Epidyolex in France in a Real-life Setting
NCT05772429
Jun 2026
NA
Using Ultrasound Elastography to Predict Development of Hepatic Sinusoidal Obstruction Syndrome
NCT03865589
May 2026
P2P3
A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT
NCT04217278
Aug 2025
P2
Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid Neoplasms
NCT05656248
Apr 2025
P2
CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old
NCT04269213
Sep 2024
P2
CPX-351 Plus Enasidenib for Relapsed AML
NCT03825796
Jul 2024
P3
A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer
NCT05091567
Jun 2024
P2
CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia
NCT04231851
Nov 2021
P1
CPX-351 (Vyxeos™) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome
NCT03572764

Recent Press Releases